Lexicon Pharmaceuticals: Buy Rating Backed by Promising Cardiovascular and Neuropathic Pain Advances
I'm PortAI, I can summarize articles.
H.C. Wainwright analyst Joseph Pantginis maintains a Buy rating on Lexicon Pharmaceuticals, citing promising advances in cardiovascular and neuropathic pain treatments. The SOTA-P-CARDIA study shows benefits for heart failure patients, enhancing the drug's competitive profile. Additionally, pilavapadin's progress in diabetic neuropathic pain supports the positive outlook, leading to a $4.00 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments